Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q1 FY21 Earnings Presentation
21 slides from Cohance Lifesciences's earnings presentation, June 2025
Slide 1: Suven Pharma Earnings Presentation Q1 FY21
SUVEN PHARMA Earnings Presentation Q1 FY21
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 11 Table of Operation & Financial Company Background Contents Performance Q1FY21 3
Slide 4: Operation & Financial Performance Q1 FY21
Operation & Financial Performance Q1 FY21 4
Slide 5: Businesswise data
Businesswise data CDMO CDMO Formulations & Pharma Spec Chem Other Services 1,276 136 970 Rupees Mn Rupees Mn Rupees Mn Q1FY21 Q1FY21 Q1FY21 5
Slide 6: Financial Snapshot – Q1FY21
Financial Snapshot – Q1FY21 Q1FY21 Q1FY20 Growth in Growth in Growth in Revenue PAT EBIDTA 28.34% 52.57% 42.66% 22.09% 8.41% 12.33% 6
Slide 7: Key Ratios
Key Ratios Q1FY21 Q1FY20 PAT to EBITDA to Cash Flow to Income Income Income 33.29% 48.30% 36.19% 37.49% 52.50% 40.24% 7
Slide 8: Financials Q1FY21
Financials Q1FY21 Revenue EBIDTA PAT EPS 2,440 812 7.22 7.19 1,178 749 1,998 1,049 5.83 1,901 826 532 Rupees Mn Rupees Mn Rupees Mn Rupees Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 8
Slide 9: Financials Q1FY21
Financials Q1FY21 EBITDA Margin (%) PAT Margin (%) 61% 46% 39% 38% 54% 53% Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 9
Slide 10: Financial Table – Q1 FY21
Financial Table – Q1 FY21 Standalone Consolidated Q1 FY21 Q4 FY20 Q-o-Q Q1 FY20 Y-o-Y Q1 FY21 Q4 FY20 Q-o-Q Q1 FY20 Y-o-Y ` ` Growth ` Growth ` ` Growth ` Growth Quarter ended June 30‘ 2020 Million Million % Million % Million Million % Million % Revenue 2,439.72 1,901.05 28.34% 1,998.36 22.09% 2,439
Slide 11: Company Background
Company Background PHARMA
Slide 12: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 12
Slide 13: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Consolidated Revenues, EBITDA and process research & across the entire CDMO Adj. PAT of Rs 2440 Mn, Rs 1281 Mn dev
Slide 14: Suven is an integrated Contract Development and Manufacturing Operations company
Suven is an integrated Contract Development and Manufacturing Operations company Suven Life Sciences provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since o
Slide 15: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 15 15
Slide 16: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 16
Slide 17: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities research capabilities Present across the to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 17
Slide 18: Business Drivers
Business Drivers Execution Capabilities Over 90% of Working with revenues from innovator companies regulated in developed markets markets having stringent Long term regulations – commercial supply reflection of our opportunity with research skills Repeat business the launch of owing to long product
Slide 19: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 20: Contact
Contact For queries and requests, please contact: Venkatraman Sunder, VP, Corporate Affairs Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Email: vsunder@suvenpharm.com # 8-2-334, SDE Serene Chambers, For more info: www.suvenpharm.com 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-
Slide 21: Thank You
Thank You 6 SUVEN PHARMA
Suven Pharmaceuticals — Q1 FY21 Earnings Presentation on 6ix